Display options
Cite
Piérard GE, Piérard-Franchimont C, Delvenne P. Malignant melanoma and its stromal nonimmune microecosystem. J Oncol. 2012;2012:584219doi: 10.1155/2012/584219.
Piérard, G. E., Piérard-Franchimont, C., & Delvenne, P. (2012). Malignant melanoma and its stromal nonimmune microecosystem. Journal of oncology, 2012584219. https://doi.org/10.1155/2012/584219
Piérard, Gérald E, et al. "Malignant melanoma and its stromal nonimmune microecosystem." Journal of oncology vol. 2012 (2012): 584219. doi: https://doi.org/10.1155/2012/584219
Piérard GE, Piérard-Franchimont C, Delvenne P. Malignant melanoma and its stromal nonimmune microecosystem. J Oncol. 2012;2012:584219. doi: 10.1155/2012/584219. Epub 2012 Jun 28. PMID: 22811710; PMCID: PMC3395267.
Copy Download .nbib Format: NLM
Share it on

J Oncol. 2012;2012:584219. doi: 10.1155/2012/584219. Epub 2012 Jun 28.

Malignant melanoma and its stromal nonimmune microecosystem.

Journal of oncology

Gérald E Piérard, Claudine Piérard-Franchimont, Philippe Delvenne

Affiliations

  1. Department of Dermatopathology, Liège University Hospital, 4000 Liège, Belgium.

PMID: 22811710 PMCID: PMC3395267 DOI: 10.1155/2012/584219

Abstract

In recent years, rapid advances were reached in the understanding of a series of biologic signals influencing cutaneous malignant melanoma (CMM) cells. CMM is in close contact with a peculiar dermal extracellular matrix (ECM). Stromal cells store and release various structural ECM components. The impact on CMM growth and progression is mediated through strong and long-lasting effects of ECM products. This paper summarizes some peculiar aspects of the peri-CMM stroma showing intracytoplasmic loads in Factor XIIIa, CD34, versican, and α (IV) collagen chains. The restricted peri-CMM skin territory exhibiting such changes corresponds to the area showing neoangiogenesis and extravascular unicellular metastatic spread. The latter inconspicuous migratory CMM cells possibly correspond to CMM stem cells or to CMM cells with aberrant HOX gene expression. Their presence is associated with an increased risk for metastases in the regional sentinel lymph nodes. In conclusion, the CMM-stroma connection appears crucial to the growth regulation, invasiveness and initial metastatic spread of CMM cells. Although much remains to be learned in this field, the active intervention of the peri-CMM stroma is likely involved in the inconspicuous early metastatic migration of CMM cells.

References

  1. Mol Med Rep. 2010 Nov-Dec;3(6):1035-9 - PubMed
  2. Cancer Res. 2005 Oct 15;65(20):9328-37 - PubMed
  3. Int J Oncol. 2004 Jan;24(1):211-6 - PubMed
  4. Am J Pathol. 2002 Feb;160(2):549-57 - PubMed
  5. J Cutan Pathol. 2000 Feb;27(2):67-75 - PubMed
  6. Pigment Cell Melanoma Res. 2008 Feb;21(1):39-55 - PubMed
  7. Rev Med Liege. 2012 Feb;67(2):64-8 - PubMed
  8. Ann Surg. 2011 Jan;253(1):116-22 - PubMed
  9. Semin Cutan Med Surg. 1996 Dec;15(4):326-35 - PubMed
  10. Adv Anat Pathol. 2007 May;14(3):195-201 - PubMed
  11. J Pathol. 2005 Sep;207(1):83-90 - PubMed
  12. Nature. 2001 May 17;411(6835):375-9 - PubMed
  13. J Dermatol Sci. 2000 Aug;23(3):170-7 - PubMed
  14. J Biol Chem. 2011 Jan 14;286(2):1475-85 - PubMed
  15. Pigment Cell Melanoma Res. 2008 Oct;21(5):520-4 - PubMed
  16. J Invest Dermatol. 2006 Jan;126(1):142-53 - PubMed
  17. Virchows Arch. 1997 Jun;430(6):433-43 - PubMed
  18. J Clin Pathol. 2011 Dec;64(12):1108-11 - PubMed
  19. Lab Invest. 2006 Sep;86(9):889-901 - PubMed
  20. Int J Cancer. 1993 Jul 30;54(6):1010-6 - PubMed
  21. Histopathology. 1994 Jan;24(1):33-40 - PubMed
  22. Int J Mol Med. 2009 Sep;24(3):295-301 - PubMed
  23. Int J Cancer. 2005 Apr 10;114(3):436-41 - PubMed
  24. Cell. 2011 Jul 8;146(1):148-63 - PubMed
  25. Mod Pathol. 2007 Jan;20(1):102-7 - PubMed
  26. Int J Cancer. 2005 May 10;114(6):879-86 - PubMed
  27. Nat Rev Cancer. 2005 Apr;5(4):275-84 - PubMed
  28. Rev Med Liege. 2008 Oct;63(10):579-84 - PubMed
  29. Onco Targets Ther. 2012;5:31-46 - PubMed
  30. Exp Ther Med. 2011 May;2(3):379-384 - PubMed
  31. Cancer Lett. 2007 Oct 18;256(1):49-55 - PubMed
  32. Melanoma Res. 2005 Apr;15(2):107-10 - PubMed
  33. N Engl J Med. 1986 Dec 25;315(26):1650-9 - PubMed
  34. Oncol Rep. 2008 Jun;19(6):1367-72 - PubMed
  35. Clin Sci (Lond). 2006 Jan;110(1):21-35 - PubMed
  36. Br J Dermatol. 1990 Dec;123(6):783-6 - PubMed
  37. Am J Clin Dermatol. 2011 Apr 1;12(2):77-86 - PubMed
  38. J Cutan Pathol. 2009 Jan;36(1):39-43 - PubMed
  39. BMC Med Genomics. 2008 Apr 28;1:13 - PubMed
  40. Melanoma Res. 2005 Jun;15(3):161-8 - PubMed
  41. Dermatol Res Pract. 2012;2012:684032 - PubMed
  42. Eur J Med Res. 2008 Nov 24;13(11):500-4 - PubMed
  43. Anticancer Agents Med Chem. 2012 Sep;12(7):773-82 - PubMed
  44. Virchows Arch. 2008 Nov;453(5):485-9 - PubMed
  45. J Biol Chem. 2001 Nov 30;276(48):45184-92 - PubMed
  46. Cancer Biomark. 2007;3(4-5):203-9 - PubMed
  47. Int J Mol Med. 2011 Feb;27(2):269-75 - PubMed
  48. ISRN Dermatol. 2012;2012:828146 - PubMed
  49. Pathol Biol (Paris). 2012 Apr;60(2):149-53 - PubMed
  50. Nature. 2008 Jan 17;451(7176):345-9 - PubMed
  51. Eur J Cancer. 1997 Oct;33(11):1888-92 - PubMed
  52. Dermatol Res Pract. 2012;2012:362784 - PubMed
  53. Virchows Arch. 1996 Sep;429(1):43-8 - PubMed
  54. Int J Mol Med. 2008 Oct;22(4):403-9 - PubMed
  55. J Cutan Pathol. 1999 Feb;26(2):78-83 - PubMed
  56. Am J Pathol. 2004 Jan;164(1):193-203 - PubMed
  57. Adv Exp Med Biol. 2012;727:186-98 - PubMed
  58. Chin Med J (Engl). 2010 Sep;123(18):2607-12 - PubMed
  59. Arch Dermatol Res. 2012 Jul;304(5):397-400 - PubMed
  60. Mol Cancer Ther. 2012 Apr;11(4):888-97 - PubMed
  61. J Cutan Pathol. 1997 Apr;24(4):212-8 - PubMed
  62. Int J Cancer. 2012 Sep 1;131(5):1071-82 - PubMed
  63. Eur J Dermatol. 2010 May-Jun;20(3):302-7 - PubMed
  64. Cancer Res. 2011 Nov 1;71(21):6561-6 - PubMed
  65. J Submicrosc Cytol Pathol. 1997 Jan;29(1):19-28 - PubMed
  66. Curr Opin Cell Biol. 2002 Oct;14(5):617-23 - PubMed
  67. Arch Dermatol Res. 2009 Aug;301(7):487-95 - PubMed
  68. Int J Mol Med. 1999 Oct;4(4):403-6 - PubMed
  69. J Invest Dermatol. 2012 Feb;132(2):385-93 - PubMed
  70. Curr Opin Biotechnol. 2003 Oct;14(5):538-46 - PubMed
  71. J Eur Acad Dermatol Venereol. 2006 Sep;20(8):980-7 - PubMed
  72. Am J Vet Res. 2007 Dec;68(12):1376-85 - PubMed
  73. Appl Immunohistochem Mol Morphol. 2007 Dec;15(4):421-5 - PubMed
  74. Differentiation. 2002 Dec;70(9-10):561-73 - PubMed
  75. Dermatologica. 1990;180(1):51-3 - PubMed
  76. Expert Rev Anticancer Ther. 2009 Nov;9(11):1583-98 - PubMed
  77. J Cutan Pathol. 1999 May;26(5):222-6 - PubMed
  78. Cancer Metastasis Rev. 1990 Jul;9(1):21-34 - PubMed
  79. J Cutan Pathol. 1998 Nov;25(10):553-8 - PubMed
  80. J Surg Res. 2000 Dec;94(2):153-8 - PubMed
  81. J Clin Oncol. 2007 Apr 20;25(12):1606-20 - PubMed
  82. J Cell Biol. 1998 Aug 10;142(3):873-81 - PubMed
  83. J Cutan Pathol. 2008 May;35(5):433-44 - PubMed
  84. J Pathol. 2003 Jul;200(4):429-47 - PubMed
  85. Nature. 2007 Feb 22;445(7130):851-7 - PubMed
  86. Crit Rev Oncog. 1993;4(5):559-94 - PubMed
  87. Lancet Oncol. 2002 Jan;3(1):35-43 - PubMed
  88. Cell Mol Life Sci. 2003 Jun;60(6):1049-60 - PubMed
  89. Stem Cells. 2008 Dec;26(12):3008-17 - PubMed
  90. Curr Top Med Chem. 2012;12(1):32-49 - PubMed
  91. Cancer Res. 2003 Dec 15;63(24):8939-47 - PubMed
  92. Br J Dermatol. 2005 Oct;153(4):733-9 - PubMed
  93. Int J Cancer. 2010 Sep 1;127(6):1308-20 - PubMed
  94. Am J Dermatopathol. 2009 Jun;31(4):331-41 - PubMed
  95. Pathology. 2004 Oct;36(5):485-90 - PubMed

Publication Types